This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.



X Parameter:FL1+
Y Parameter:FL2+

Quad	% Gated
UL	6.82
UR	12.59
LL	44.09
LR	36.50



X Parameter:FL1+
Y Parameter:FL2+

Quad	% Gated
UL	3.96
UR	13.40
LL	6.35
LR	76.29

Fig. 1a

CD34+/38-



X Parameter:FL1-
Y Parameter:FL2-

Quad	% Gated
UL	17.14
UR	1.80
LL	75.27
LR	5.79

CD34+/Lin-



X Parameter:FL1-
Y Parameter:FL2-

Quad	% Gated
UL	15.58
UR	3.18
LL	30.18
LR	51.06

Fig. 1b

CD34+/38-



X Parameter:FL1-
Y Parameter:FL2-

Quad	% Gated
UL	17.16
UR	2.43
LL	74.12
LR	6.29

CD34+/Lin-



X Parameter:FL1-
Y Parameter:FL2-

Quad	% Gated
UL	11.91
UR	5.54
LL	23.45
LR	59.09

Fig. 1c

Fold expansion (2w) CD34+



control	13
antagonist 10-5M	18
antagonist 10-7M	24

Fig. 2a

Fold expansion (2w) CD34+/38-



control	36
antagonist 10-5M	903
antagonist 10-7M	1320

Fig. 2b

Fold expansion (2w) CD34+/Lin-



control	8
antagonist 10-5M	518
antagonist 10-7M	585

Fig. 2c



	time-0	2 weeks	9 weeks	11 weeks
control	20	258	0	0
antagonist 10-5M	20	353	18347	32427
antagonist 10-7M	20	486	14080	17067

Fig. 3a



	time-0	2 weeks	9 weeks	11 weeks
control	0.28	10	0	0
antagonist 10-5M	0.28	253	11960	18983
antagonist 10-7M	0.28	370	1864	1080

Fig. 3b



	time-0	2 weeks	9 weeks	11 weeks
control	0.1024	1	0	0
antagonist 10-5M	0.1024	53	1268	1670
antagonist 10-7M	0.1024	60	355	321

Fig. 3c


RAR Antagonist 10-7 M
No. of cells X 10^4
No. of CFU X 10^3
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
80000
70000
60000
50000
40000
30000
20000
10000
0
0
5
10
15
20
weeks
CD34+ cells
CFU

Fig. 4



Fig. 5a Negative Control, IgG PE/IgG FITC



Control, 2 weeks, $CD34^+$ Lin^-

Quad	% Gated
UL	1.60
UR	95.79
LL	0.03
LR	2.58

Fig. 5b



RA antagonist, 10^{-5}M, 2 weeks, $CD34^+$ Lin^-

Quad	% Gated
UL	36.89
UR	62.77
LL	0.14
LR	0.20

Fig. 5c



RA antagonist, 10^{-7}M, 11 weeks, $CD34^+$ Lin^-

Quad	% Gated
UL	1.88
UR	94.95
LL	0.15
LR	3.03

Fig. 5d



RA antagonist, 10^{-5}M, 11 weeks, $CD34^+$ Lin^-

Quad	% Gated
UL	5.15
UR	79.08
LL	0.07
LR	15.71

Fig. 5e



Fig. 6a



Fig. 6b



Fig. 7



Fig. 8a



Fig. 8b



Fig. 9a



Fig.9b

Fig. 9c

Fig. 10a

Fig. 10b

Fig. 10c

Fig. 10d

Fig. 11a



Fig. 11b

Fig. 11c

Fig. 11d

Fig. 11e



Fig. 11f

3 weeks-(34/Lin FACS analysis)

Control-cytokines only



File:ex.43(3w)3.12.02.005
SampleID:
X Parameter:FL1-H(Log)
Y Parameter:FL2-H(Log)

Quad	% Gated
UL	0.04
UR	98.99
LL	0.22
LR	0.75

RAR antagonist 10-7M



File:ex.43(3w)3.12.02.011
SampleID:
X Parameter:FL1-H(Log)
Y Parameter:FL2-H(Log)

Quad	% Gated
UL	8.19
UR	85.41
LL	0.44
LR	5.96

RAR+RXR antagonist 10-7M



File:ex.43(3w)3.12.02.020
SampleID:
X Parameter:FL1-H(Log)
Y Parameter:FL2-H(Log)

Quad	% Gated
UL	19.75
UR	79.79
LL	0.09
LR	0.37

Fig. 12a

5 weeks-(34/Lin FACS analysis)

*Control(only cytokines) -The number of cells was not sufficient for FACS analysis.

RAR antagonist 10-7M



File:ex.42(5w)18.12.02.008
Sample ID:
X Parameter:FL1-H(Log)
Y Parameter:FL2-H(Log)

Quad	% Gated
UL	3.19
UR	91.04
LL	0.39
LR	5.37

RAR+RXR antagonist 10-7M



File:ex.42(5w)18.12.02.010
Sample ID:
X Parameter:FL1-H(Log)
Y Parameter:FL2-H(Log)

Quad	% Gated
UL	17.38
UR	81.18
LL	0.08
LR	1.36

Fig. 12b



	3 weeks	5 weeks
control	74	0
RAR 10-7	33	41
RXR 10-7	0	0
RAR+RXR 10-7	220	379

Fig. 13a



	3 weeks	5 weeks
control	0.37	0
RAR 10-7	30	36
RXR 10-7	0	0
RAR+RXR 10-7	177	336

Fig. 13b



	3 weeks	5 weeks
control	0.03	0
RAR 10-7	2.7	1.31
RXR 10-7	0	0
RAR+RXR 10-7	43.47	65.79

Fig. 13c



	3 weeks	5 weeks
control	5088	5952
RAR 10-7	3024	2496
RXR 10-7	96	0
RAR+RXR 10-7	4464	11904

Fig. 13d



	3 weeks	5 weeks
control	768	0
RAR 10-7	547	211
RXR 10-7	0	0
RAR+RXR 10-7	1037	1632

Fig. 13e



Fig. 14



Fig. 15



Fig. 16



Fig. 17

FACS analysis

34/38

Control-cytokines only



Quad	% Gated
UL	0.14
UR	99.44
LL	0.12
LR	0.30

Nicotinamide 5 mM



Quad	% Gated
UL	34.67
UR	62.28
LL	1.24
LR	1.80

Fig. 18a

FACS analysis: CD34/Lin

Control-cytokines only



Quad	% Gated
UL	0.02
UR	99.08
LL	0.05
LR	0.85

Nicotinamide 5 mM



Quad	% Gated
UL	16.58
UR	80.08
LL	0.05
LR	3.29

Fig. 18b

FACS analysis: 34/HLA-DR+38

Control-cytokines only



Quad	% Gated
UL	0.02
UR	99.02
LL	0.12
LR	0.84

Nicotinamide 5 mM



Quad	% Gated
UL	1.02
UR	95.43
LL	0.16
LR	3.39

Fig. 18c